Clinical Trial Update: KD019 and Trastuzumab in Patients With Esophagus, Gastroesophageal Junction and Stomach Cancer [Phase 1]

View source ↗

Summary

This clinical trial update reports the withdrawal of a Phase 1 study evaluating KD019 in combination with Trastuzumab for esophageal, gastroesophageal junction,…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer
• Gastroesophageal Junction Cancer
• Stomach Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• KD019

Snippet

Sponsor: NYU Langone Health | Conditions: Esophageal Cancer, Stomach Cancer | Phase 1 | Status: WITHDRAWN